

Are your **MRI contrast agents** cost-effective?

Learn more about generic **Gadolinium-Based Contrast Agents**.



**FRESENIUS
KABI**

caring for life

AJNR

**The Challenge of an Acute Antithrombotic
Regimen for Treatment of Tandem Lesions
Stroke**

P. Papanagiotou and B. Gory

AJNR Am J Neuroradiol 2021, 42 (5) 926

doi: <https://doi.org/10.3174/ajnr.A7122>

<http://www.ajnr.org/content/42/5/926>

This information is current as
of April 17, 2024.

The Challenge of an Acute Antithrombotic Regimen for Treatment of Tandem Lesions Stroke

In the treatment of tandem stroke, several studies have shown the efficacy and safety of endovascular treatment. However, there are many unanswered questions regarding this treatment strategy including technical aspects as well as peri- and postprocedural antithrombotic management. The extracranial lesion is usually treated by acute stent placement, but balloon angioplasty can be performed as an alternative. Data from the TITAN Registry and German Stroke Registry support that acute stent placement is associated with a better clinical outcome compared with balloon angioplasty in treating extracranial lesions.^{1,2} The main disadvantage of acute stent placement is the potential risk for stent thrombosis with re-occlusion of the internal carotid artery.

In the current issue of *AJNR*, Pop et al³ report 2 important findings regarding acute stent placement in tandem lesions. First, the rate of stent thrombosis was not insignificant, with a frequency of 14.5%. Although data from large registries regarding stent patency are limited, other authors report the thrombosis risk after acute stent placement as up to 45%.⁴ The second important finding was that the highest risk of stent thrombosis was observed during the first 24 hours, and stent thrombosis beyond the first day was rare. Both findings suggest that the current acute antithrombotic regimen is not appropriate for preventing acute stent thrombosis.

The major questions that arise are: 1) Can we avoid acute stent thrombosis? 2) Can the acute antithrombotic regimen be improved? and 3) Can we be more aggressive with the antithrombotic medication in the acute phase? A more aggressive scheme is not without risks, as additional antithrombotic agents may increase the risk of intracerebral hemorrhagic complications, which is the major concern in the endovascular treatment of acute stroke. Therefore, properly calibrating the acute antithrombotic regimen in tandem stroke remains an important challenge.

There are heterogeneous antithrombotic regimens in use by various interventionalists and centers, which limits our complete understanding of this topic. We do not know which agents and what dosing should be applied in the acute setting. What we do know is that an antiplatelet agent is necessary for peri-interventional care to avoid stent occlusion. Platelets are now known to have a pivotal role in thrombosis and inflammation after vessel injury.⁵ Some patients receive antiplatelet agents with their pre-stroke medication. These patients are likely to be at low risk of stent thrombosis, and therefore, an aggressive antiplatelet strategy could be avoided. In the remaining patients, acute peri-

interventional antiplatelet agents should be applied to prevent stent thrombosis. Agents that can be used include intravenous aspirin, clopidogrel, ticagrelor, and glycoprotein IIb/IIIa inhibitors (GPIs), or the new drug, cangrelor. Aspirin and clopidogrel inhibit 2 vital pathways of platelet activation; however, this effect does not occur immediately after usage. In contrast, GPIs directly block the most abundant receptor on the platelet surface and are highly effective. Although, if given at full dosage, a substantially increased risk of bleeding is known to occur with GPIs.⁶

The high rate of acute stent thrombosis in treatment of tandem lesions stroke highlights the challenge of acute antiplatelet therapy. Future studies should focus on establishing an optimal antithrombotic regimen.

REFERENCES

1. Papanagiotou P, Haussen DC, Turjman F, et al. **Carotid stenting with antithrombotic agents and intracranial thrombectomy leads to the highest recanalization rate in patients with acute stroke with tandem lesions.** *JACC Cardiovasc Interv* 2018;11:1290–99 CrossRef Medline
2. Feil K, Herzberg M, Dorn F, et al. **Tandem lesions in anterior circulation stroke: analysis of the German stroke registry-endovascular treatment.** *Stroke* 2021 Feb 21 [Epub ahead of print] CrossRef Medline
3. Pop R, Hasiu A, Mangin PH, et al. **Postprocedural antiplatelet treatment after emergent carotid stenting in tandem lesions stroke: impact on stent patency beyond day 1.** *AJNR Am J Neuroradiol* 2021;42:921–25 CrossRef Medline
4. Yilmaz U, Körner H, Mühl-Benninghaus R, et al. **Acute occlusions of dual-layer carotid stents after endovascular emergency treatment of tandem lesions.** *Stroke* 2017;48:2171–75 CrossRef Medline
5. Prasad A, Herrmann J. **Myocardial infarction due to percutaneous coronary intervention.** *N Engl J Med* 2011;364:453–64 CrossRef Medline
6. Yousuf O, Bhatt DL. **The evolution of antiplatelet therapy in cardiovascular disease.** *Nat Rev Cardiol* 2011;8:547–59 CrossRef Medline

 P. Papanagiotou

Department of Radiology

Areteion University Hospital, National and Kapodistrian University of Athens

Athens, Greece

Department of Diagnostic and Interventional Neuroradiology

Hospital Bremen-Mitte

Bremen, Germany

 B. Gory

Department of Diagnostic and Therapeutic Neuroradiology

Université de Lorraine

Nancy, France

<http://dx.doi.org/10.3174/ajnr.A7122>